InsidersTradesSigma
Total declarations
Companies
▲ Purchases (12 ops.)
▼ Sales (1 ops.)
Insider track record
OtherDisclosed buys
12
Disclosed sells
1
T+90 hit rate
80%
T+90 mean return
+12.8%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Fairmount Funds Management LLC. Officer active across 7 companies, notably Viridian Therapeutics, Inc.\DE. In total, 30 disclosures have been published. Breakdown: 12 buys · 1 sell. Total volume traded: €83.5m. Activity tracked since 21 September 2021. The latest transaction was disclosed on 27 September 2024 (J). Regulator: SEC (Form 4). The full history is free.
Declarations30 total
666,680 sharesCommon StockSEC:0001104659-26-076967:0
4,684,781 sharesCommon StockSEC:0001104659-26-076967:1
160,000 sharesCommon StockSEC:0001213900-24-101116:0
62,146 shares0Common StockSEC:0001104659-24-105106:0
41,130 sharesCommon StockSEC:0001104659-24-100766:0
1,600,000 shares@ US$18.7542.9% of flowCommon StockSEC:0001104659-24-100769:0
Ideal exit: 10 Jun 2025 (T+270)
41,130 sharesCommon StockSEC:0001104659-24-100330:0
275,000 shares@ US$23.00100.0% of flowCommon StockSEC:0001213900-24-078633:0
1,500,000 sharesCommon StockSEC:0000950170-24-072639:0
3,639,680 shares0Common StockSEC:0000950170-24-048457:0
286,851 sharesCommon StockSEC:0000950170-24-039588:0
55,913 sharesCommon StockSEC:0001104659-24-041998:0
58,857 sharesCommon StockSEC:0000950170-24-039590:0
5,859 sharesCommon StockSEC:0000950170-24-039599:0
1,166,666 shares@ US$7.5030.8% of flowCommon StockSEC:0000950170-24-016610:0
892,529 shares0Common StockSEC:0001104659-24-008835:0
476,190 shares@ US$21.0014.5% of flowCommon StockSEC:0000950170-24-007123:0
Ideal exit: 18 Oct 2024 (T+270)
834,334 shares@ US$12.0088.3% of flowCommon StockSEC:0000950170-24-007136:0
3,435,480 shares0Common StockSEC:0000950170-23-073904:0
3,435,480 shares0Common StockSEC:0000950170-23-066399:0
24,670 shares@ US$13.633.1% of flowCommon StockSEC:0001104659-23-106378:0
Ideal exit: 25 Jun 2024 (T+270)
30,000 shares@ US$13.1541.7% of flowCommon StockSEC:0001104659-23-104808:0
Ideal exit: 22 Jun 2024 (T+270)
30,000 shares@ US$13.2030.6% of flowCommon StockSEC:0000899243-23-019370:0
Ideal exit: 15 Jun 2024 (T+270)
14,887 shares@ US$10.851.4% of flowCommon StockSEC:0000950170-23-048022:0
Ideal exit: 8 Jun 2024 (T+270)
55,913 shares@ US$17.00100.0% of flowCommon StockSEC:0001104659-23-081729:0
Ideal exit: 8 Apr 2024 (T+270)
25 of 30 declarations
About Fairmount Funds Management LLC
Fairmount Funds Management LLC has filed 30 declarations, all sampled, between September 23, 2021, and June 23, 2026. Recent transactions include acquisitions, with a total of 83,492,906 EUR in purchases and no sales. The top filings include a purchase of 27,081,000 EUR in Viridian Therapeutics, Inc. on September 17, 2024, and another purchase of 9,823,978 EUR in the same company on August 19, 2022.
